Full archive
Pharmacogenomics
Week of 25 August 2026
8 articles
Geno'X Veille — genox-veille.fr
Key takeaways this week
- ►226,053 participants: 93.7% carry at least one actionable pharmacogenomic phenotype.
- ►CYP2C9 — etrasimod: simulated dose reduction to 1 mg in poor metabolizers with hepatic impairment.
- ►Paediatric oncology: 93% of children carry an actionable phenotype across 13 pharmacogenes.
- ►CYP2D6 — poorer antidepressant response in poor and intermediate metabolizers.
8 articles of 8
Sort
Adverse drug reactions
PubMedGenomics-first association of pharmacogenomic risk phenotypes with adverse drug reactions in a healthcare-based population.
Adverse drug reactions
7
Adverse reactionPreemptive genotyping
Genet Med 2026· AugRead
Oncology
PubMedPharmacogenetic variants in the molecular characterization initiative: a report from the children's oncology group.
Pediatric cancers
7
OncologyPreemptive genotyping
J Natl Cancer Inst 2026· AugRead
CYP2C9
PubMedModel-informed dose optimization of etrasimod in ulcerative colitis across CYP2C9 genotypes and hepatic impairment.
Ulcerative colitis
6
DiabetesDose recommendation
Br J Clin Pharmacol 2026· AugRead
Psychiatry
PubMedOptimization of individualized antidepressant drug administration strategies based on pharmacogenomics and its clinical validation study.
Depression
6
PsychiatryPreemptive genotypingAdverse reaction
Psychiatry Res 2026· AugRead
CYP2D6
PubMedAssociation between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder: a retrospective cohort study.
Major depressive disorder treated with antidepressants
6
PsychiatryCPIC Level AAdverse reaction
Pharmacogenomics J 2026· AugRead
UGT1A1
PubMedUGT1A1 gene polymorphisms and their impact on plasma trough concentrations of dolutegravir in Chinese adults with human immunodeficiency virus-1 infection.
HIV-1 infection treated with dolutegravir
5
Recurrent variant
Chin Med J (Engl) 2026· AugRead
CYP2D6
PubMedApplication of Physiologically Based Pharmacokinetic Modeling to Optimize Assessment of Age-Related Fluoxetine Accumulation in the Elderly.
Fluoxetine exposure in elderly patients
4
Dose recommendation
CPT Pharmacometrics Syst Pharmacol 2026· AugRead
CYP2D6
PubMedPharmacogenomics in Dentistry: From CYP-Mediated Drug Response to Precision Prescribing in Oral Healthcare.
Drug prescribing in oral healthcare
4
PhenoconversionAdverse reaction
Oral Dis 2026· AugRead
References and sources
- Adverse drug reactions. Genet Med 2026. PMID 42621698. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42621698/
- CYP2C9 — Ulcerative colitis. Br J Clin Pharmacol 2026. PMID 42610655. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42610655/
- Depression. Psychiatry Res 2026. PMID 42628152. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42628152/
- Pediatric cancers. J Natl Cancer Inst 2026. PMID 42636256. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42636256/
- CYP2D6 — Major depressive disorder treated with antidepressants. Pharmacogenomics J 2026. PMID 42618567. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42618567/
- CYP2D6 — Fluoxetine exposure in elderly patients. CPT Pharmacometrics Syst Pharmacol 2026. PMID 42631653. Score 4/10. https://pubmed.ncbi.nlm.nih.gov/42631653/
- UGT1A1 — HIV-1 infection treated with dolutegravir. Chin Med J (Engl) 2026. PMID 42634956. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42634956/
- CYP2D6 — Drug prescribing in oral healthcare. Oral Dis 2026. PMID 42630019. Score 4/10. https://pubmed.ncbi.nlm.nih.gov/42630019/
